Memantine - Children's Medical Center Corporation

Drug Profile

Memantine - Children's Medical Center Corporation

Alternative Names: Akatinol; Axura; Ebixa; Extended-release memantine capsules - Allergan; Memantine hydrochloride; Memary; Namenda; Namenda XR; SUN Y7017; SUNY 017

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Childrens Medical Center Corporation
  • Developer Allergan; Daiichi Sankyo Company; Forest Laboratories; Lundbeck A/S; Merz Pharma; Neurobiological Technologies; University of California, Davis
  • Class Amines; Analgesics; Antidementias; Antiparkinsonians; Antispastics; Antitussives; Organic bridged compounds; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Cognition disorders; Dementia
  • Discontinued Asperger syndrome; Autistic disorder; Diabetic neuropathies; Fragile X syndrome; Glaucoma; Neuropathic pain; Vascular dementia

Most Recent Events

  • 12 Sep 2017 Daiichi Sankyo completes a clinical trial for Alzheimer's disease in Japan (UMIN000016420)
  • 31 May 2017 Daiichi Sankyo completes a phase III trial for Alzheimer's disease in Japan (JapicCTI-163209)
  • 26 Apr 2017 Daiichi Sankyo and Katayama Medical Clinic terminates a clinical trial for Alzheimer's disease (Combination therapy) in Japan (UMIN000021140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top